Why Immix Biopharma Shares Are Surging Today?

  • Immix Biopharma Inc IMMX announced it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 (formerly HBI0101).
  • In an ongoing Phase 1b study, NXC-201 showed an overall response rate (ORR) of 85% and 71% complete response/stringent complete response (CR/sCR) at the therapeutic dose from the first 20 patients with relapsed/refractory multiple myeloma.
  • NXC-201 also produced 100% ORR and 100% organ response rate in 4 relapsed/refractory AL Amyloidosis patients. 
  • In addition, zero neurotoxicity of any grade and events of immune effector cell-associated neurotoxicity syndrome (ICANs) were observed.
  • Also see: ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug.
  • Immix Biopharma has formed a wholly-owned subsidiary, Nexcella Inc, to develop and potentially commercialize NXC-201.
  • The formation of Nexcella is expected to have a minimal impact on Immix Biopharma's financial position, as Nexcella, Inc is expected to be an independently financed company.
  • "Considering its short 2-day median CRS duration, occurring within a median 1-day post-dosing, we look forward to exploring outpatient administration of NXC-201," added Gabriel Morris, CFO of Immix Biopharma.
  • Price Action: IMMX shares are up 41.08% at $2.07 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!